Skip to main content

H.R. 4697

Referred to Committee

Prevent Drug Addiction Act of 2016

Introduced 3/3/2016•114th Congress•House

Latest Action

Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

4/1/2016 • House

Summary

Prevent Drug Addiction Act of 2016

This bill amends the Public Health Service Act to require the Substance Abuse and Mental Health Services Administration (SAMHSA) to award grants for consumer education about opioid addiction. (Opioids are drugs with effects similar to opium, such as heroin or certain prescription painkillers.)

This bill amends the Controlled Substances Act to require medical practitioners to be trained in the treatment of opioid-dependent patients, pain management, and early detection of opioid addiction before they can be registered by the Drug Enforcement Administration to dispense opioids.

Opioid treatment programs that close on any day must make arrangements for each patient to receive treatment during the closure, as necessary.

A report must be submitted to SAMHSA for each individual who dies while receiving treatment in an opioid treatment program. In states receiving funding for controlled substance monitoring programs, deaths where an opioid drug is detected in the body must be reported to SAMHSA.

The National Center for Health Statistics of the Centers for Disease Control and Prevention must establish a National Opioid Death Registry to track opioid-related deaths.

The Agency for Healthcare Research and Quality must develop and apply prescription drug addiction prevention and treatment quality measures.

This bill amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act to allow prescription drug plan (PDP) sponsors to limit the access of certain beneficiaries to addictive drugs. PDP sponsors must have a utilization management tool to prevent drug addiction.

Medicare Drug Integrity Contractors may accept prescription and medical records to determine whether a beneficiary is at risk for prescription drug addiction.

Introduced in House • 3/3/2016

Enter your district to see how this bill affects your community
-

Topics & Subjects

Policy Area: Health
Congressional oversightConsumer affairsDrug trafficking and controlled substancesDrug, alcohol, tobacco useGovernment information and archivesGovernment studies and investigationsHealth care qualityHealth information and medical recordsHealth personnelHealth promotion and preventive careMedical educationMedicarePrescription drugs

Congressional Votes (0)

No recorded votes yet

Roll call votes will appear here as the bill moves through Congress

Related Federal Spending

Sponsor & Cosponsors (4)

Party Breakdown

2
Democrats
2
Republicans
0
Independents

Sponsor

R[
Rep. Esty, Elizabeth H. [D-CT-5]

Democrat • CT-5

Sponsored 3/3/2016

Cosponsors (3)

R[
Rep. Costello, Ryan A. [R-PA-6]

R-PA-6

Joined 3/3/2016

R[
Rep. Knight, Stephen [R-CA-25]

R-CA-25

Joined 3/3/2016

R[
Rep. Courtney, Joe [D-CT-2]

D-CT-2

Joined 4/20/2016

Bill Journey

Originated in the House

Introduced

March 3, 2016

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Committee Review

Floor Debate

Passed Chamber

Other Chamber

President

Enacted into Law

Text Versions (1)

Introduced in House3/3/2016

Details

Bill TypeHR
Current StatusReferred to Committee
Cosponsors3